



NEWS RELEASE

TFS HealthScience Standardizes on Veeva Vault Clinical Operations Suite to Accelerate Clinical Development

3/25/2021

Veeva Vault unifies clinical documents and processes to improve collaboration and speed execution

PLEASANTON, Calif.--(BUSINESS WIRE)-- **Veeva Systems** (NYSE: VEEV) today announced that TFS HealthScience selected **Veeva Vault Clinical Operations Suite** for end-to-end study management on a single cloud platform. The global CRO is taking action to further modernize study operations, adopting the entire suite for greater efficiency and speed in trials. Now TFS HealthScience will offer its biopharma customers industry-leading technologies and services to run more cost-efficient and compliant studies.

"Veeva Vault Clinical Operations Suite gives us a foundation for further growth as we expand our service offerings globally," said Dr. Bassem Saleh, CEO, TFS HealthScience. "Bringing together study operations streamlines processes, enabling us to maximize value for sponsors and accelerate the delivery of treatments to patients."

TFS HealthScience provides customers with strategically tailored solutions focused on driving excellence and innovation to reduce complexity in trials. Building on its success with **Veeva Vault eTMF** to maintain inspection readiness, the company will use **Veeva Vault Study Startup** to get studies up and running quickly, **Veeva Vault CTMS** to keep studies on track, and **Veeva Vault Payments** to simplify payments to global partner sites. With a connected, agile clinical landscape, TFS HealthScience will centralize governance and study oversight to share insights with sponsors easily.

"With Veeva Vault, we now have complete visibility into study progress and deviations to make better, more informed decisions and ensure studies meet their objectives," said Young Shon, CIO, TFS HealthScience. "Our



partnership with Veeva is instrumental to TFS's digital transformation program and our strategic push towards paperless and patient-centric approaches."

"TFS HealthScience is transforming clinical operations to work more efficiently and better serve sponsors," said Pinar Benet, senior director strategy, Vault Clinical Operations at Veeva Systems. "We're excited to continue this journey together towards unified and connected trials to accelerate clinical research."

Vault Clinical Operations Suite enables sponsors and CROs to seamlessly share information and documents across CTMS, eTMF, study start-up, and payments for better collaboration and increased efficiency throughout the study lifecycle.

The **Veeva Unified Clinical Operations Survey: Annual CRO Report** shows that CROs like TFS HealthScience are moving to streamline trial execution by embracing new digital strategies and technologies that eliminate data silos and manual processes. Learn how CROs are modernizing clinical operations to speed trials in the full report, available online at veeva.com/CROReport.

Additional Information

Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems

Follow @veevasystems on Twitter: twitter.com/veevasystems

About TFS HealthScience

TFS HealthScience is a global contract research organization (CRO) that supports biotechnology and pharmaceutical companies throughout their entire clinical development journey. In partnership with customers, we build solution-driven teams working for a healthier future. Bringing together nearly 700 professionals, TFS delivers tailored clinical research services in more than 40 countries and supports customers with comprehensive solutions through three strong business models: clinical development services (CDS), which provides full-service support at all stages of the clinical development process, strategic resourcing solutions (SRS), which offers expert insourcing and targeted recruitment services, and functional services (FSP), to provide customers with strategic workforce management solutions. For more information, visit www.tfscro.com

About Veeva Systems

Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 975 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing

the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit [veeva.com](https://www.veeva.com).

Forward-looking Statements

This release contains forward-looking statements, including the market demand for and acceptance of Veeva's products and services, the results from use of Veeva's products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva's historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva's expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva's financial results are included under the captions, "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations," in the company's filing on Form 10-Q for the period ended October 31, 2020. This is available on the company's website at [veeva.com](https://www.veeva.com) under the Investors section and on the SEC's website at [sec.gov](https://www.sec.gov). Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20210325005264/en/): <https://www.businesswire.com/news/home/20210325005264/en/>

Deivis Mercado

Veeva Systems

925-226-8821

deivis.mercado@veeva.com

Sylwia Domagalska

TFS HealthScience

+48 787 913 074

sylwia.domagalska@tfscro.com

Source: Veeva Systems